BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Keir LS, Marks SD, Kim JJ. Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther 2012;6:195-208. [PMID: 22888220 DOI: 10.2147/DDDT.S25757] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Henrique IDM, Sacerdoti F, Ferreira RL, Henrique C, Amaral MM, Piazza RMF, Luz D. Therapeutic Antibodies Against Shiga Toxins: Trends and Perspectives. Front Cell Infect Microbiol 2022;12:825856. [DOI: 10.3389/fcimb.2022.825856] [Reference Citation Analysis]
2 Keenswijk W, Raes A, Vande Walle J. Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence. Eur J Pediatr 2018;177:311-8. [PMID: 29288280 DOI: 10.1007/s00431-017-3077-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
3 Keir LS, Saleem MA. Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 2014;29:1895-902. [PMID: 23843163 DOI: 10.1007/s00467-013-2561-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
4 Flam B, Sackey P, Berge A, Zachau AC, Brink B, Lundberg S. Diarrhea-associated hemolytic uremic syndrome with severe neurological manifestations treated with IgG depletion through immunoadsorption. J Nephrol 2016;29:711-4. [PMID: 26995001 DOI: 10.1007/s40620-016-0294-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Yosief HO, Iyer SS, Weiss AA. Binding of Pk-trisaccharide analogs of globotriaosylceramide to Shiga toxin variants. Infect Immun 2013;81:2753-60. [PMID: 23690406 DOI: 10.1128/IAI.00274-13] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
6 Riney LC, Treasure JD, Varnell CD Jr, Depinet H. Case 6: An Infant Presenting with Hematuria and Pallor. Pediatr Rev 2018;39:98-9. [PMID: 29437133 DOI: 10.1542/pir.2016-0112] [Reference Citation Analysis]
7 Myrnäs A, Castegren M. Fatal hemolytic uremic syndrome associated with day care surgery and anaesthesia: a case report. BMC Res Notes 2013;6:242. [PMID: 23803463 DOI: 10.1186/1756-0500-6-242] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
8 Li T, Tu W, Liu Y, Zhou P, Cai K, Li Z, Liu X, Ning N, Huang J, Wang S, Huang J, Wang H. A potential therapeutic peptide-based neutralizer that potently inhibits Shiga toxin 2 in vitro and in vivo. Sci Rep 2016;6:21837. [PMID: 26903273 DOI: 10.1038/srep21837] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
9 Luna M, Kamariski M, Principi I, Bocanegra V, Vallés PG. Severely ill pediatric patients with Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) who suffered from multiple organ involvement in the early stage. Pediatr Nephrol 2021;36:1499-509. [PMID: 33205220 DOI: 10.1007/s00467-020-04829-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Liu Y, Tian S, Thaker H, Dong M. Shiga Toxins: An Update on Host Factors and Biomedical Applications. Toxins (Basel) 2021;13:222. [PMID: 33803852 DOI: 10.3390/toxins13030222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Lee Y, Kim MH, Alves DR, Kim S, Lee LP, Sung JH, Park S. Gut-Kidney Axis on Chip for Studying Effects of Antibiotics on Risk of Hemolytic Uremic Syndrome by Shiga Toxin-Producing Escherichia coli. Toxins (Basel) 2021;13:775. [PMID: 34822559 DOI: 10.3390/toxins13110775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Rumore J, Tschetter L, Kearney A, Kandar R, McCormick R, Walker M, Peterson CL, Reimer A, Nadon C. Evaluation of whole-genome sequencing for outbreak detection of Verotoxigenic Escherichia coli O157:H7 from the Canadian perspective. BMC Genomics 2018;19:870. [PMID: 30514209 DOI: 10.1186/s12864-018-5243-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
13 Zheng L, Zhang D, Cao W, Song WC, Zheng XL. Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy. Blood 2019;134:1095-105. [PMID: 31409673 DOI: 10.1182/blood.2019001040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
14 Rosso DA, Rosato M, Gómez FD, Álvarez RS, Shiromizu CM, Keitelman IA, Ibarra C, Amaral MM, Jancic CC. Human Glomerular Endothelial Cells Treated With Shiga Toxin Type 2 Activate γδ T Lymphocytes. Front Cell Infect Microbiol 2021;11:765941. [PMID: 34900753 DOI: 10.3389/fcimb.2021.765941] [Reference Citation Analysis]
15 Zadravec P, Marečková L, Petroková H, Hodnik V, Perišić Nanut M, Anderluh G, Štrukelj B, Malý P, Berlec A. Development of Recombinant Lactococcus lactis Displaying Albumin-Binding Domain Variants against Shiga Toxin 1 B Subunit. PLoS One 2016;11:e0162625. [PMID: 27606705 DOI: 10.1371/journal.pone.0162625] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
16 Vaterodt L, Holle J, Hüseman D, Müller D, Thumfart J. Short- and Long-Term Renal Outcome of Hemolytic-Uremic Syndrome in Childhood. Front Pediatr 2018;6:220. [PMID: 30131950 DOI: 10.3389/fped.2018.00220] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
17 Lo NC, Turner NA, Cruz MA, Moake J. Interaction of Shiga toxin with the A-domains and multimers of von Willebrand Factor. J Biol Chem 2013;288:33118-23. [PMID: 24097977 DOI: 10.1074/jbc.M113.487413] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]